Agenus Inc. (NASDAQ:AGEN - Get Free Report) has been given an average rating of "Hold" by the six research firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $10.00.
Separately, HC Wainwright reaffirmed a "neutral" rating on shares of Agenus in a research report on Wednesday, January 22nd.
View Our Latest Report on AGEN
Agenus Stock Down 10.9 %
Shares of NASDAQ:AGEN traded down $0.31 during midday trading on Friday, reaching $2.54. The company's stock had a trading volume of 397,939 shares, compared to its average volume of 396,888. Agenus has a 12-month low of $2.50 and a 12-month high of $19.69. The firm has a market capitalization of $59.59 million, a P/E ratio of -0.23 and a beta of 1.31. The firm has a 50 day moving average of $3.30 and a 200-day moving average of $4.00.
Hedge Funds Weigh In On Agenus
Hedge funds have recently added to or reduced their stakes in the company. Corton Capital Inc. bought a new stake in shares of Agenus in the 4th quarter worth $36,000. Virtu Financial LLC bought a new stake in Agenus in the 4th quarter worth about $51,000. Apollon Wealth Management LLC purchased a new position in Agenus in the 4th quarter worth about $55,000. EP Wealth Advisors LLC purchased a new position in Agenus in the 3rd quarter worth about $55,000. Finally, Bank of Montreal Can bought a new position in Agenus during the 4th quarter valued at about $69,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.
About Agenus
(
Get Free ReportAgenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Stories
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
